- Home
- OBIO vs MRCC Comparison
OBIO vs MRCC Comparison
Compare OBIO & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- MRCC
- Stock Information
- Founded
- OBIO 2017
- MRCC 2011
- Country
- OBIO United States
- MRCC United States
- Employees
- OBIO N/A
- MRCC N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- MRCC Investment Managers
- Sector
- OBIO Health Care
- MRCC Finance
- Exchange
- OBIO Nasdaq
- MRCC Nasdaq
- Market Cap
- OBIO 146.2M
- MRCC 151.7M
- IPO Year
- OBIO N/A
- MRCC 2012
- Fundamental
- Price
- OBIO $2.74
- MRCC $7.03
- Analyst Decision
- OBIO Strong Buy
- MRCC Hold
- Analyst Count
- OBIO 4
- MRCC 1
- Target Price
- OBIO $14.00
- MRCC $8.00
- AVG Volume (30 Days)
- OBIO 227.6K
- MRCC 101.8K
- Earning Date
- OBIO 11-11-2025
- MRCC 11-11-2025
- Dividend Yield
- OBIO N/A
- MRCC 14.20%
- EPS Growth
- OBIO N/A
- MRCC N/A
- EPS
- OBIO N/A
- MRCC 0.09
- Revenue
- OBIO $2,944,000.00
- MRCC $51,229,000.00
- Revenue This Year
- OBIO $29.26
- MRCC N/A
- Revenue Next Year
- OBIO $10.65
- MRCC N/A
- P/E Ratio
- OBIO N/A
- MRCC $79.69
- Revenue Growth
- OBIO 41.61
- MRCC N/A
- 52 Week Low
- OBIO $2.20
- MRCC $5.96
- 52 Week High
- OBIO $6.50
- MRCC $8.85
- Technical
- Relative Strength Index (RSI)
- OBIO 59.98
- MRCC 39.45
- Support Level
- OBIO $2.20
- MRCC $6.90
- Resistance Level
- OBIO $2.89
- MRCC $7.13
- Average True Range (ATR)
- OBIO 0.14
- MRCC 0.18
- MACD
- OBIO 0.04
- MRCC -0.05
- Stochastic Oscillator
- OBIO 78.26
- MRCC 13.79
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.